Goldman Sachs Downgrades Alere (ALR) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
- US orders diplomats to depart Saudi Arabia amid Houthi strikes
Jefferies Downgrades Alere (ALR) to Hold Following Takeover
February 2, 2016 7:58 AM ESTJefferies downgraded Alere (NYSE: ALR) from Buy to Hold with a price target of $56.00 (from $54.00) after the company agreed to be acquired by Abbott Laboratories.
For an analyst ratings summary and ratings history on Alere... More
Canaccord Genuity Downgrades Alere (ALR) to Hold
February 2, 2016 7:55 AM ESTCanaccord Genuity downgraded Alere (NYSE: ALR) from Buy to Hold.
For an analyst ratings summary and ratings history on Alere click here. For more ratings news on Alere click here.
Shares of Alere closed at $54.11 yesterday.
... MoreAbbott (ABT) to Acquire Alere (ALR) for $56/Share
February 1, 2016 8:02 AM ESTAbbott (NYSE: ABT) and Alere Inc. (NYSE: ALR) announced today a definitive agreement for Abbott to acquire Alere, significantly advancing Abbott's global diagnostics presence and leadership. Under the terms of the agreement, Abbott will pay $56 per common share at a total expected equity value of $5.8 billion. Once the transaction is completed, Abbott will become the leading diagnostics provider of point of care testing. Abbott's total diagnostics sales will exceed $7 billion after the close.
Abbott will be able to provide new, flexible, cost-effective, high-quality products to help health systems meet... More



